Impact of <i><scp>KRAS</scp></i> mutation on response and outcome of patients with stage <scp>III</scp> non‐squamous non‐small cell lung cancer
Shigehiro Yagishita, Yuichiro Ohe(National Cancer Center), Kouya Shiraishi, Takashi Kohno(Gunma University), Koh Furuta(Teikyo University Chiba Medical Center), Noboru Yamamoto(Tokyo National Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Yutaka Fujiwara(Aichi Cancer Center), Hidehito Horinouchi(Tokyo National Hospital), Kuniko Sunami(Tokyo National Hospital), Tomohide Tamura(St. Luke's International Hospital), Shintaro Kanda(Shinshu University Hospital), Koji Tsuta(Kansai Medical University), Hiroshi Nokihara(Tokushima University Hospital)
Cited by 23
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|599
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537